The long-term goal of this project is to develop new ways in which chelated metal ions may be used in the detection and treatment of cancer. Bifunctional chelating agents are important to this work; these compounds contain a powerful metal-chelating group and may be attached covalently to biological molecules such as monoclonal antibodies or drugs such as bleomycin. The products form stable chelates with more than 50 chemical elements; these elements have many useful properties -- such as radioactivity, paramagnetism, luminescence, and catalytic activity -- which have current and future applications in medical diagnosis and treatment.
Specific aims are to use newly prepared monoclonal anti-chelate antibodies to strongly enhance the tumor localization of chelate-tagged bleomycin analogs and other chelate radiopharmaceuticals, and to investigate the mechanism(s) by which tumor uptake of chelate-tagged bleomycins is increased (by an order of magnitude) in the presence of anti-chelate antibodies. The versatile chemistry of the new BLEDTA IV synthesis -- which links bleomycin to chelators and other groups via coordination to inert cobalt(III), with no covalent modification of bleomycin -- will be used to prepare tumor-localizing bleomycin analogs bearing side-chains which may have cytotoxic properties or act as photoaffinity labels for mechanistic studies. The use of chelate-tagged antitumor antibodies with metabolically cleavable linkages between antibody and chelate will be explored with the aim of improving tumor imaging by reducing background interference. New bifunctional chelators with macrocyclic structures will be prepared, aimed at preventing any loss of metal from chelate during metabolism and thus minimizing potential toxic side effects of certain procedures. The methodology involves chemical synthesis and purification, chemical modification of proteins (antibodies), trace metal chelation chemistry, and a large number of associated analytical procedures. The proposed studies should provide information relevant to a number of advanced technical methods, including nuclear medicine, radioimmunotherapy, nuclear magnetic resonance imaging, and immunoassay.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA016861-17
Application #
3481752
Study Section
Metallobiochemistry Study Section (BMT)
Project Start
1978-06-01
Project End
1995-05-31
Budget Start
1991-06-01
Budget End
1992-05-31
Support Year
17
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Arts and Sciences
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Marquez, Bernadette V; Beck, Heather E; Aweda, Tolulope A et al. (2012) Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation. Bioconjug Chem 23:1080-9
Aweda, Tolulope A; Meares, Claude F (2012) Combination of isothermal titration calorimetry and time-resolved luminescence for high affinity antibody-ligand interaction thermodynamics and kinetics. Methods 56:145-53
Aweda, Tolulope A; Eskandari, Vahid; Kukis, David L et al. (2011) New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation. Bioconjug Chem 22:1479-83
Aweda, Tolulope A; Beck, Heather E; Wu, Anna M et al. (2010) Rates and equilibria for probe capture by an antibody with infinite affinity. Bioconjug Chem 21:784-91
Day, Jeffrey J; Marquez, Bernadette V; Beck, Heather E et al. (2010) Chemically modified antibodies as diagnostic imaging agents. Curr Opin Chem Biol 14:803-9
Wei, Liu H; Olafsen, Tove; Radu, Caius et al. (2008) Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med 49:1828-35
Corneillie, Todd M; Whetstone, Paul A; Meares, Claude F (2006) Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting. J Inorg Biochem 100:882-90
Butlin, Nathaniel G; Meares, Claude F (2006) Antibodies with infinite affinity: origins and applications. Acc Chem Res 39:780-7
Whetstone, Paul A; Akizawa, Hiromichi; Meares, Claude F (2004) Evaluation of cleavable (Tyr3)-octreotate derivatives for longer intracellular probe residence. Bioconjug Chem 15:647-57
Corneillie, Todd M; Lee, Kelvin C; Whetstone, Paul A et al. (2004) Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands. Bioconjug Chem 15:1392-402

Showing the most recent 10 out of 71 publications